Kornimate/medical-research-clean huggingface dataset:
effect of chest physiotherapy on the development of preterm infants.

Conditions: Development, Infant; Respiratory Distress Syndrome in Premature Infant

Summary: the aim of this study is to investigate the effect of the stimulation of "reflex rolling" from the vojta method and the effect of the expiratory flow increase technique on the development of the preterm infants. in the same way, it will be assessed whether the application of these techniques produce pain. this application will be carried out in preterm infants of less than 32 weeks of gestation with neonatal respiratory distress syndrome (sdr) and carriers of mechanical ventilation. the intervention will take place in the neonatal intensive care unit (nicu) the intervention period is one month (4 weeks) and different follow-ups will be carried out at term age, at 3, 6, 9 and 12 months of corrected age.


Eligibility criteria:
inclusion criteria: * preterm infants \<32 gestational age * admitted to the nicu * with sdr * hemodynamically stable * stable convulsive pictures * controlled thermoregulation * mechanical ventilation (invasive or non-invasive) * parents / guardians of legal age, with sufficient cognitive ability to understand consent * signature of consent exclusion criteria: * periventricular leukomalacia * grade iii and iv intraventricular hemorrhage * rib fracture * asphyxia at birth * necrotizing enterocolitis \> or = ii b abandoned criteria: * appearance of any of the complications mentioned above * hospital transfer * hospital discharge (if the intervention at home cannot be followed) * voluntary decision of parents / guardians to abandon the study * medical decision

Keywords: premature infant respiratory distress syndrome chest physiotherapy development
covid-19 and sars-cov-2 antibodies in multiple sclerosis patients

Conditions: Multiple Sclerosis

Summary: rationale: patients with ms are possibly more vulnerable to infection with sars-cov-2. furthermore the use of immunomodulatory treatment could have an effect on the course of covid-19 disease. this has resulted in an alteration of current immunomodulatory treatment strategies and delaying the start of certain medications, which could induce ms disease activity. however, certain immunomodulatory treatments are also hypothesized to have a positive effect on covid-19 disease. besides lack of information regarding the effects of ms treatments on covid-19, there is significant uncertainty in how we should advise ms patients in terms of self-isolation, resulting in many patients staying at home reluctant to perform their work or other daily activities. nationally and locally, we are collecting information regarding covid-19 in ms patients but numbers are low and only those who are severely affected are tested. furthermore, there is no information regarding sars-cov-2 immunity in ms patients, which could be affected by certain ms treatments. consequently, there is an urgent need for reliable information about infection rates/immunity and course of covid-19 in relation to ms characteristics and treatments. objectives: the objectives of this study are 1. to study the course of covid-19 in ms patients in relation to immunomodulatory treatment and other patient and ms characteristics and 2. to study the proportion of ms patients with sars-cov-2 antibodies and 3. to establish the antibody profile in positive tested patients and 4. to study the longitudinal course of these antibody profiles in positive tested patients. study design: this is a mono-center cohort study in patients of the ms center amsterdam. study population: all patients with a diagnosis of ms currently under follow-up in the amsterdam ms center. intervention (if applicable): single venous puncture for drawing blood and questionnaire. for a minority of patients (max 25%) who test positive for antibodies we will draw blood a again with questionnaires after six and twelve months. main study parameters/endpoints: course of covid-19 in ms patients in relation to ms immunomodulatory treatment.


Eligibility criteria:
inclusion criteria: * a current diagnosis of multiple sclerosis and age ≥18 years. exclusion criteria: * lack of informed consent.
bright white light therapy for the improvement of sleep, fatigue, distress, depression, and anxiety in hospitalized leukemia patients

Conditions: Acute Leukemia; Recurrent Leukemia; Refractory Leukemia

Summary: this trial investigates how well bright white light therapy works in improving sleep, fatigue, distress, depression, and anxiety, side effects that are often experienced during an intense leukemia treatment regimen, in hospitalized leukemia patients. bright white light therapy may help to control these symptoms, and information from this study may help doctors and nurses learn more about methods for decreasing these symptoms.

primary objective: i. to assess the efficacy of bright white light therapy (bwlt) on fatigue in patients diagnosed with leukemia during their hospitalization. secondary objectives: i. to assess the efficacy of bwlt on sleep disturbance in patients diagnosed with leukemia during their hospitalization. i. to assess the efficacy of bwlt on anxiety in patients diagnosed with leukemia during their hospitalization. iii. to assess the efficacy of bwlt on depression in patients diagnosed with leukemia during their hospitalization. iv. to assess the efficacy of bwlt on distress in patients diagnosed with leukemia during their hospitalization. outline: patients are randomized to 1 of 2 groups. group i: patients receive bwlt over 30 minutes in addition to standard of care daily during hospital stay. group ii: patients receive standard of care during hospital stay.

Eligibility criteria:
inclusion criteria: * admitted to the acute leukemia unit for an anticipated stay of 3 weeks or longer * english speaking * able to comprehend and sign a consent form * able to read and complete surveys * alert and oriented * without bwlt for seven days prior to initiating the trial exclusion criteria: * current eye disorders which is defined as: * iritis, uveitis, keratitis, cataract, glaucoma, macular degeneration, retinal detachment, or retinitis pigmentosa * diagnosed bipolar disorder * persons with pacemakers * the manufacturer of the bwlt unit used for this study mentions the light unit contains magnets
an open-label study of vascazen in cardiac rehab patients with deficient blood omega-3 fatty acid levels

Conditions: Dyslipidemia

Summary: the investigators aim to test the hypothesis that dietary supplementation with vascazen will correct omega-3 deficiency in cardiac rehab patients and improve biochemical risk factors.


Eligibility criteria:
inclusion criteria: * adult subjects (\> or = 18 years of age) * enrolled in cardiac rehabilitation clinic with documented cardiovascular disease as assessed by the principle investigator * has had cardiovascular examination within the past 2 months exclusion criteria: * subjects who refuse to provide written consent * subjects with medical conditions, as determined by the principal investigator, which prevented them from study participation * subjects with a known bleeding or clotting disorder * subjects with known allergies to fish * subjects with an implantable cardiac defibrillator * subjects with a heart transplant * female subjects who are currently taking hormone replacement therapy * subjects who are pregnant or planning on becoming pregnant * subjects currently taking omega-3 fatty acid supplements (either under medical supervision or self-administered)

Keywords: fatty acids, omega-3 omega-3 fatty acids docosahexaenoic acid (dha) eicosapentaenoic acid (epa) docosapentaenoic acid (dpa) omega index omega score cardiac rehab
a study of idasanutlin in combination with obinutuzumab in relapsed/refractory (r/r) follicular lymphoma (fl) and in combination with rituximab in r/r diffuse large b-cell lymphoma (dlbcl) participants

Conditions: Non-Hodgkin's Lymphoma

Summary: this is a open-label, multicenter, non-randomized, study to evaluate the safety, efficacy, and pharmacokinetics of idasanutlin in combination with obinutuzumab in participants with r/r fl and rituximab in combination with idasanutlin in r/r dlbcl. the study will include an initial dose-escalation phase followed by an expansion phase. the dose-escalation phase is designed to determine the recommended phase 2 dose (rp2d) for idasanutlin in combination with obinutuzumab for fl and in combination with rituximab for dlbcl. the expansion phase is designed to further assess the safety and efficacy of obinutuzumab in combination with idasanutlin at the rp2d with the selected regimen in participants with r/r fl and of rituximab in combination with idasanutlin at the rp2d in participants with r/r dlbcl.


Eligibility criteria:
inclusion criteria: * eastern cooperative oncology group (ecog) performance status of 0, 1, or 2 * histologically documented cluster of differentiation (cd) 20-positive b-cell lymphoma classified as relapsed or refractory fl or dlbcl after treatment with at least two prior chemoimmunotherapy regimens that included an anti-cd20 monoclonal antibody (mab) and for which no other more appropriate treatment option exists * at least one bidimensionally measurable lesion * agreement to remain abstinent or use adequate contraception, among women or men of childbearing potential exclusion criteria: * known cd20-negative status at relapse or progression * prior allogeneic stem cell transplantation (sct), or autologous sct within 100 days prior to day 1 of cycle 1 * current use of systemic corticosteroids greater than (\>) 20 mg prednisone per day (or equivalent), or prior anti-cancer therapy to include: radioimmunoconjugate within 12 weeks; mab or antibody-drug conjugate within 4 weeks; or radiotherapy/chemotherapy/hormone therapy/targeted small-molecule therapy within 2 weeks prior to day 1 of cycle 1 * requirement for chronic anticoagulation * central nervous system (cns) disease * active infection * positive for human immunodeficiency virus (hiv) or hepatitis b or c * receipt of a live virus vaccine within 28 days prior to day 1 of cycle 1 * poor hematologic, renal, or hepatic function * pregnant or lactating women * history of progressive multifocal leukoencephalopathy (pml)
empyema following pneumonectomy for non small cell lung cancer (nsclc)

Conditions: Non Small Cell Lung Cancer; Lung Cancer

Summary: empyema following pneumonectomy for non small cell lung cancer (nsclc) is a known problem that occurs in about 2% of pneumonectomy patients.

the development of an empyema following pneumonectomy is a devastating complication, especially if associated with an underlying fistula. whilst the perioperative mortality of pneumonectomy overall is now less than 5%, this rises to around 25% when complicated by empyema, and about 50% when associated with fistula. in addition, there is the morbidity and social cost of long-term drainage, chronic sepsis and often multiple operations.

Eligibility criteria:
inclusion criteria: * pneumonectomy for nsclc exclusion criteria: * pneumonectomy for other reasons (infectious pathology, trauma, mesothelioma, ...)

Keywords: surgery nsclc
effect of whole grain diet on insulin sensitivity, advanced glycation end products and inflammatory markers in pre-diabetes

Conditions: Diabetes; Prediabetes

Summary: food products derived from cereal grains constitute a major part of the daily diet of many americans . for example, a typical chinese american eats rice about 9.5 times a week on an average. however, most of these foods are derived from refined grain. during the refining process grains are stripped of their bran and germ which results in depletion of several biologically active constituents including fiber, anti-oxidants, phytoestrogens and minerals. from observational studies there is evidence for a protective effect of whole-grain foods with regard to the development of type 2 diabetes. more recently, higher intake of whole grains was also associated with decreases in insulin resistance - a risk factor related to the development of type 2 diabetes. in this randomized study the investigators plan to replicate this beneficial effect of improving insulin sensitivity in patients with pre-diabetes and go a step further by exploring the potential mechanisms by which this benefit may occur. the investigators will assess the effect of consuming a whole-grain-rich diet on levels of advanced glycation endproducts (age), rage (receptor for age) and markers of inflammation and oxidative stress - all of which have been shown to play an important role in the pathogenesis of diabetes mellitus. the investigators will also look for correlations between the levels of these markers with insulin sensitivity to identify potential mechanisms of pathogenesis.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years to unlimited, both genders. 2. at least one meal per day included rice in the seven days prior to enrolment. 3. no current diagnosis of diabetes mellitus (dm). 4. fasting blood glucose value between 100 to 125 mg/dl and/or hemoglobin a1c levels between 5.7%-6.4%. 5. ≥ 2 visits with primary care physician to establish compliance exclusion criteria: 1. special diets (e.g. vegetarian) 2. use of medications that would affect blood sugar levels (e.g. steroids) 3. allergy to any type of grain 4. body weight fluctuation over the past 180 days of ≥ 10% 5. planning to significantly change level of physical activity during the time of study. 6. planning to move out of town or take a vacation for ≥ 14 days during the time of the study 7. current smoker 8. consumption of greater than 2 alcoholic drinks per day 9. history of malignancy and overt cardiovascular disease (apart from hypertension).

Keywords: diabetes prediabetes prevention whole grain advanced glycation end products insulin sensitivity
pelvic osteotomy in bladder exstrophy

Conditions: Bladder Exstrophy

Summary: the study focuses on the surgical treatment of bladder exstrophy, a congenital condition where the bladder is located outside the body. it examines the use of modified diagonal pelvic osteotomy combined with an external fixator as a treatment approach. this method aims to improve pelvic support and facilitate proper bladder reconstruction. the study likely evaluates the outcomes, complications, and overall effectiveness of this surgical technique in enhancing patient quality of life and functional results. key findings may include insights into recovery times, rates of successful bladder closure, and potential long-term benefits for patients.


Eligibility criteria:
inclusion criteria: 1. age: all cases of delayed exstrophy repaior 2. sex : both gender 3. children who received no operative treatment befor exclusion criteria: 1. previous pelvic surgery 2. sever comorbidities
recurrence following nonoperative management of 1st episode of hinchey ii diverticulitis

Conditions: Diverticulitis

Summary: patients will agree to be randomized to either surgery or observation following nonoperative management of a first episode of hinchey ii diverticulitis. information will be collected on recurrence rates and major complications in both groups.

this study will randomize patients with first episode of acute diverticulitis of the colon with extraluminal air and/or abscess as defined by ct scan following nonoperative management (npo, iv antibiotics, percutaneous drainage, and tpn followed by colonoscopy) to observation or elective resection. the primary endpoint is recurrent diverticulitis of the colon defined as an acute episode confirmed at ct scan and requiring hospitalization with iv antibiotics.

Eligibility criteria:
inclusion criteria: * older than or equal to 18 * history of resolved first episode of diverticulitis with abscess (hinchey class ii) who were successfully treated by our standard protocol * the diagnosis confirmed by colonoscopy * signed informed consent exclusion criteria: * prior episode of diverticulitis * right sided diverticulitis * failure of recovery from first episode, defined as recurrence within one month. * cancer found at the site on screening colonoscopy * comorbidities prohibiting surgery (as measured by colorectal possum score) * immunosuppressed patients * hinchey i, iii, or iv (diverticulitis with peritonitis and/or free air under the diaphragm) * patients who are unable to sign the informed consent
crp to serum albumin ratio in type 2 dm é diabetic nephropathy

Conditions: Type 2 DM /Diabetic Nephropathy

Summary: we aimed to compare c-reactive protein to serum albumin ( car) level of the t2dm patients with dn to those t2dm without dn

diabetic nephropathy (dn) is a serious complication of diabetes mellitus associated with chronic and low-grade inflammatory burden affects around 30 % of diabetic patients it is the leading cause of end-stage renal failure worldwide and associated with cardio vascular diseases and increases mortality of diabetic patients it characterized by persistent albuminuria, raise in arterial blood pressure ,decrease in glomerular filtration rate (gfr) it associated with chronic low grade inflammation that's leads to increase glucose and activities inflammation despite of the pathogenesis of dn is multifactorial, but local inflammatory process may result from both the metabolic and hemodynamic affection seen in dn sustained diabetes-related metabolic and haemodynamic perturbations can induce subclinical low-grade renal inflammation and drive kidney from repair response to damage process, eventually to renal fibrosis chronic inflammatory processes not only play a principle role in the progression of micro vascular but also macro vascular complications in type 2 diabetes mellitus. an association between low -grade inflammation and type 2 diabetes has been described in recent studies .c- reactive protein to serum albumin ratio has attracted great attention recently , and used as biomarker in detection disease severity , since type 2 diabetes mellitus and diabetic nephropathy(dn) is associated with low grade inflammation in recent studies. in this study investigator presume that c-reactive protein to serum albumin ratio ( car )levels could be associated with the progression of dn in patients with t2dm.

Eligibility criteria:
inclusion criteria all type 2diabetic patients exclusion criteria: * type 1 diabetes is , patient t with liver cirrhosis, patient with active infection ,pregnant women,patients with cancer
efficacy and mortality of a loading dose of colistin in critical ill patients

Conditions: Gram Negative Bacterial Infections

Summary: the study hypothesis is that the loading dose of intravenous colistin (6 million of international units) is associated with greater clinical and microbiological efficacy, and reduced mortality of critically ill patients infected by multidrug resistant gram- negative bacilli, compared to a scheme without loading dose.

it is a prospective, multicenter, randomized, controlled study to evaluate a scheme with and without a loading dose of 6 million international units of colistin, followed by a maintenance dose of 3 million international units every 8 hours intravenous. the study should be conducted in 3 hospitals in chile, in critically patients presenting infection by multidrug gram-negative bacteria and requiring be treated with colistin for at least 48 hours. the objectives of the study are: to evaluate the clinical and microbiological response, and mortality.

Eligibility criteria:
inclusion criteria: * patient hospitalized in critical care units * patient infected by multi drug resistant gram negative bacteria susceptibly only to colistin * source of infection: blood, respiratory, intra abdominal or urinary exclusion criteria: * pregnant or breastfeeding patients * patient with a history of hypersensitivity to colistin

Keywords: critically ill patients colistin dosing multidrug resistant bacteria
early recanalization after intravenous thrombolysis with tenecteplase versus alteplase in distal vessel occlusion strokes

Conditions: Acute Distal Vessel Occlusion Stroke

Summary: the purpose of this monocentric retrospective study is to compare, in patients with acute distal vessel occlusion stroke, the early rates of successful recanalization in patients treated with alteplase (alt) versus tenecteplase (tnk), based on a retrospective analysis of magnetic resonance imaging (mri) performed early after ivt.

early rates of successful recanalization (sr) of distal vessel occlusions (dvo) following intravenous thrombolysis (ivt) between alteplase (alt) and tenecteplase (tnk) are poorly known. from march 2016 to february 2020, consecutive stroke patients hospitalized in the stroke unit of the sud-francilien hospital with dvo identified on baseline mri and suitable for ivt but not for mechanical thrombectomy will be included. in our stroke unit, patients were treated with alt, 0.9 mg/kg from march 2016 to february 2018 and then with tnk, 0.25 mg/kg from march 2018 to december 2023. mri was controlled 1-2 hours within ivt (mri-2). early recanalization was assessed on an adapted arterial occlusion lesion (aol) scale, sr being defined as aol 2/3 scores on mri-2. the rate reduction of thrombus length (tl) when thrombus persisted, the ivt response threshold of tl and the infarct size evolution were also assessed. in the present study, the investigators sought to compare early rates of sr between the two lytics, based on a retrospective analysis of magnetic resonance imaging (mri) performed early after ivt.

Eligibility criteria:
inclusion criteria: * age≥ 18 years. * acute ischemic stroke (visible on dwi, but not visible on flair) on initial mri associated with distal arterial occlusion as defined below: * a distal occlusion of the m2 segment of the middle cerebral artery (mca) * occlusion (regardless of location) of a non-dominant m2 branch of the mca * occlusion of the m3 segment of the mca. * occlusion of the a2 or a3 segment of the anterior cerebral artery (aca) * occlusion of the p2 or p3 branch of the posterior cerebral artery (pca). * a proximal m2-mca or proximal p1-pca occlusion may also be included if not eligible for mechanical thrombectomy, especially if the initial nihss score is low (\<5). * distal arterial occlusion is identified by mri either on the tof (time of flight)-arm sequence and/or on the presence of a thrombus (susceptibility vessel sign, svs) on the swan sequence, * ivt by alt or tnk within 4h30 after onset of symptoms, * early brain mri performed 1 to 2 hours after ivt (mri n°2), * good quality mri (absence of motion artifact interfering with interpretation) with availability of dwi, flair, tof-mra and swan sequences. exclusion criteria: - patients informed of the study who objected to the collection of their data.

Keywords: acute occlusion recanalization tenecteplase alteplase thrombolysis ischemic stroke-distal